NCT06392659View on ClinicalTrials.gov

A Phase 1, Open-label Study Evaluating the Pharmacokinetics and Drug-drug Interaction of VX-993 in Healthy Adults

PHASE1CompletedINTERVENTIONAL
Enrollment

42

Participants

Timeline

Start Date

May 2, 2024

Primary Completion Date

July 2, 2024

Study Completion Date

July 2, 2024

Conditions
Pain
Interventions
DRUG

VX-993

Suspension for Oral Administration.

DRUG

Gemfibrozil

Tablets for Oral Administration.

DRUG

Itraconazole

Capsules for Oral Administration.

DRUG

Midazolam

Solution for Oral Administration.

Trial Locations (1)

Unknown

MAC Clinical Research, Manchester

All Listed Sponsors
lead

Vertex Pharmaceuticals Incorporated

INDUSTRY

NCT06392659 - A Phase 1, Open-label Study Evaluating the Pharmacokinetics and Drug-drug Interaction of VX-993 in Healthy Adults | Biotech Hunter | Biotech Hunter